Moderna Inc. Stock

"Buy when there's blood in the streets," was something famous banker Baron Rothschild once advised, suggesting the time to invest is when everyone else is fleeing a particular asset or the market in

Image source: The Motley Fool.

Moderna (NASDAQ: MRNA)Q2 2024 Earnings CallAug 01, 2024, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

Moderna (NASDAQ: MRNA) went from being an unknown biotech to a household name thanks to its work developing and marketing one of the most successful COVID-19 vaccines. Though the company has

Moderna (NASDAQ: MRNA) is best known for its work in the coronavirus vaccine market. That's why the company's stock skyrocketed in the earlier days of the pandemic. It's also why its shares have

Some investors might view Moderna (NASDAQ: MRNA) as a shooting star that shined bright for a while then flamed out. In 2022, the biotech company generated sales of nearly $18.9 billion, but it

Although Moderna (NASDAQ: MRNA) is now a somewhat famous biotech, it was a relatively unknown, clinical-stage company just five years ago. Its success in the COVID-19 vaccine market catapulted it to

The shortened trading week that ended on May 31 was a strange one for the vaccine developer Moderna (NASDAQ: MRNA). Biotech stocks generally rise after a product they spent years developing earns

Moderna (NASDAQ: MRNA) jumped into the limelight when it started developing a coronavirus vaccine candidate. And the stock soared as the vaccine raced across the finish line and went on to bring in

Shares of Moderna (NASDAQ: MRNA) were sinking 9% lower this week as of Thursday's market close, according to data provided by S&P Global Market Intelligence. The decline appears to be the result of

The past two-and-a-half years have been rough for Moderna (NASDAQ: MRNA). Though the biotech was highly successful in the COVID-19 vaccine market, investors rightly expecting this niche to shrink

Shares of vaccine stocks Moderna (NASDAQ: MRNA), Novavax (NASDAQ: NVAX), and BioNTech SE (NASDAQ: BNTX) rallied this week, appreciating 23.4%, 16.4%, and 9.3%, respectively, through Thursday

Moderna (NASDAQ: MRNA) isn't new to artificial intelligence (AI). The biotech best known for its billion-dollar coronavirus vaccine has been using this hot technology for years to help it save

Novavax (NASDAQ: NVAX) and Moderna (NASDAQ: MRNA) both entered the coronavirus vaccine race around the same time, in early pandemic days, and their shares soared -- in fact, Novavax rose the most

Investors have put their hopes in Moderna's (NASDAQ: MRNA) next potential product, a respiratory syncytial virus (RSV) vaccine. That's because it represents a new revenue stream for a company that

Equities have been on a bull run for well over a year. Though it might be tempting to invest in stocks that have largely been in tandem with the broader market, it's even better to consider those

Moderna (NASDAQ: MRNA) and OpenAI are collaborating to bring artificial intelligence (AI) to every level of the biotech's operations, and the implications could perhaps be significant for investors

Five years ago, pharmaceutical company Moderna (NASDAQ: MRNA) was mostly unknown. It was developing vaccines that induce human immune cells to more effectively fight disease. But the science of

Moderna (NASDAQ: MRNA) was a fine stock to heal an ailing portfolio on the second-to-last trading day of the week. The company, which developed and sells the Spikevax COVID-19 vaccine, saw its share

Image source: The Motley Fool.

Moderna (NASDAQ: MRNA)Q1 2024 Earnings CallMay 02, 2024, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

Moderna (NASDAQ: MRNA) stock soared earlier in the pandemic as the company developed its coronavirus vaccine and the product went on to generate billions of dollars in sales. But as demand for the

According to some new data revealed by Moderna (NASDAQ: MRNA) at the American Association for Cancer Research Annual Meeting on April 8, the biotech responsible for the Spikevax coronavirus vaccine

For many, Moderna (NASDAQ: MRNA) stock is yesterday's news. The stock earned a great deal of attention during the coronavirus pandemic, as it was one of the early developers of a vaccine to fight

Before the COVID-19 pandemic, most investors likely hadn't heard of Moderna (NASDAQ: MRNA). At the end of 2019, it was a relatively small biotech company with only collaboration and grant revenue

Moderna (NASDAQ: MRNA) shot to stardom in the early days of the pandemic as it brought its coronavirus vaccine from drawing board to commercialization in less than a year -- and then went on to

It's always possible to come up with a justification for why someone should sell their shares of a stock, but that doesn't make every justification correct. For a company like Moderna (NASDAQ: MRNA)